Contributors |
|
xv | |
Preface |
|
xxv | |
Volumes in Series |
|
xvii | |
|
Section I Identification and Measurement of Constitutive Activity |
|
|
1 | |
|
1 Constitutive Activity at the Cannabinoid CB1 Receptor and Behavioral Responses |
|
|
3 | (28) |
|
|
|
|
4 | (2) |
|
|
6 | (6) |
|
|
12 | (14) |
|
|
26 | (5) |
|
2 Detecting Constitutive Activity and Protean Agonism at Cannabinoid-2 Receptor |
|
|
31 | (22) |
|
|
|
|
|
|
32 | (2) |
|
|
34 | (1) |
|
3 Evaluation of Constitutive Activity Using GTPγS Assay |
|
|
35 | (4) |
|
4 Evaluation of Constitutive Activity Using cAMP Assay |
|
|
39 | (3) |
|
5 Evaluation of Constitutive Activity Using RT-CES |
|
|
42 | (4) |
|
6 Evaluation of Protean Agonism with cAMP Assay |
|
|
46 | (2) |
|
7 Comparison of the Methods |
|
|
48 | (1) |
|
|
49 | (4) |
|
3 Modulation of the Constitutive Activity of the Ghrelin Receptor by Use of Pharmacological Tools and Mutagenesis |
|
|
53 | (22) |
|
|
|
|
54 | (1) |
|
2 The Ghrelin Receptor and its Constitutive Activity |
|
|
55 | (2) |
|
3 Structural Basis of Constitutive Activity |
|
|
57 | (4) |
|
4 Residues Responsible for the Inverse Agonism and Efficacy Swap |
|
|
61 | (4) |
|
5 Physiological Relevance of Constitutive Activity |
|
|
65 | (1) |
|
6 Experimental Procedures |
|
|
66 | (3) |
|
|
69 | (6) |
|
4 Assessment of Constitutive Activity and Internalization of GPR54 (KISS1-R) |
|
|
75 | (20) |
|
|
|
|
76 | (1) |
|
|
77 | (2) |
|
|
79 | (12) |
|
|
91 | (1) |
|
|
92 | (3) |
|
5 Assessment of Constitutive Activity in E-Type Prostanoid Receptors |
|
|
95 | (14) |
|
|
|
|
|
96 | (1) |
|
2 Assays Used to Assess EP3 Receptor Constitutive Activity |
|
|
97 | (8) |
|
3 Assays Used to Assess EP4 Receptor Constitutive Activity |
|
|
105 | (2) |
|
|
107 | (2) |
|
6 α1D-Adrenergic Receptors: Constitutive Activity and Reduced Expression at the Plasma Membrane |
|
|
109 | (18) |
|
|
|
|
|
110 | (1) |
|
|
111 | (3) |
|
|
114 | (3) |
|
4 Plasma Membrane α1D-Adrenergic Receptors |
|
|
117 | (2) |
|
5 Possible Physiological Implications |
|
|
119 | (2) |
|
|
121 | (1) |
|
|
121 | (6) |
|
7 Constitutive Activity of the Histamine H1 Receptor |
|
|
127 | (22) |
|
|
|
|
|
128 | (5) |
|
2 Methods to Study Constitutive H1R Signaling |
|
|
133 | (9) |
|
3 Constitutive Activity as Tool to Elucidate Receptor Activation and Crosstalk |
|
|
142 | (2) |
|
|
144 | (1) |
|
|
144 | (1) |
|
|
145 | (4) |
|
8 Constitutive Activity of Somatostatin Receptor Subtypes |
|
|
149 | (16) |
|
|
|
|
|
150 | (1) |
|
2 Choosing Cells to be Studied |
|
|
151 | (1) |
|
|
152 | (11) |
|
|
163 | (1) |
|
|
163 | (2) |
|
9 Assessment of Homologous Internalization of Constitutively Active N111G Mutant of AT1 Receptor |
|
|
165 | (14) |
|
|
|
|
166 | (1) |
|
2 Preparation of Receptor Plasmid and Protein |
|
|
167 | (1) |
|
3 Radioligand Binding Assay |
|
|
168 | (2) |
|
4 Inositol Phosphate Accumulation Assay |
|
|
170 | (1) |
|
|
171 | (2) |
|
|
173 | (1) |
|
|
174 | (1) |
|
|
175 | (1) |
|
|
175 | (4) |
|
10 Methods to Detect Cell Surface Expression and Constitutive Activity of GPR6 |
|
|
179 | (18) |
|
|
|
|
|
180 | (1) |
|
2 GPR6 is Expressed in Intracellular Compartments |
|
|
180 | (7) |
|
3 Comparison of the Cell Surface Protein Detection Methods |
|
|
187 | (5) |
|
4 Comparison of the Constitutive Gs-Activity Detection Methods |
|
|
192 | (2) |
|
|
194 | (1) |
|
|
194 | (3) |
|
11 β3-Adrenoceptor Agonists and (Antagonists as) Inverse Agonists: History, Perspective, Constitutive Activity, and Stereospecific Binding |
|
|
197 | (34) |
|
|
|
|
198 | (3) |
|
|
201 | (13) |
|
|
214 | (10) |
|
|
224 | (1) |
|
|
225 | (6) |
|
12 Constitutive Activity of the Lutropin Receptor and Its Allosteric Modulation by Receptor Heterodimerization |
|
|
231 | (22) |
|
|
|
232 | (3) |
|
2 General Principles for Quantifying Receptor Activation |
|
|
235 | (4) |
|
3 Modifying Cell Surface Expression Levels of Recombinant hLHR and Mutants Thereof |
|
|
239 | (4) |
|
4 Quantifying Cell Surface hLHR Expression |
|
|
243 | (2) |
|
5 Quantifying cAMP Production in Cells Expressing the hLHR |
|
|
245 | (1) |
|
6 Experimental Strategies for Characterizing the Attenuating Effects of a Signaling Inactive hLHR on a Coexpressed wt or CAM hLHR |
|
|
246 | (4) |
|
|
250 | (1) |
|
|
250 | (3) |
|
13 Assessing Constitutive Activity of Extracellular Calcium-Sensing Receptors in Vitro and in Bone |
|
|
253 | (14) |
|
|
|
|
|
254 | (4) |
|
|
258 | (4) |
|
|
262 | (1) |
|
|
263 | (2) |
|
|
265 | (1) |
|
|
265 | (2) |
|
14 Constitutive Activity of Neural Melanocortin Receptors |
|
|
267 | (14) |
|
|
|
|
|
|
|
|
268 | (1) |
|
2 Signaling Assay for the Neural Melanocortin Receptors |
|
|
268 | (2) |
|
3 Naturally Occuring Constitutively Active MC4R Mutants |
|
|
270 | (3) |
|
4 Inverse Agonism of AgRP at the MC3R |
|
|
273 | (1) |
|
5 Computational Modeling of the Constitutively Active MC4R Mutants |
|
|
273 | (4) |
|
|
277 | (1) |
|
|
277 | (4) |
|
15 Measurement of Constitutive Activity of BMP Type I Receptors |
|
|
281 | (14) |
|
|
|
|
|
281 | (3) |
|
2 Determining ALK2 Constitutive Activity |
|
|
284 | (5) |
|
3 Determining the Effects of ALK2 Constitutive Activity on Osteoblast Differentiation |
|
|
289 | (2) |
|
|
291 | (1) |
|
|
292 | (1) |
|
|
292 | (3) |
|
16 Probing the Constitutive Activity Among Dopamine D1 and D5 Receptors and Their Mutants |
|
|
295 | (34) |
|
|
|
|
|
|
|
296 | (3) |
|
2 Design of Genetically Modified D1-Like Receptor Constructs and Cloning Strategy |
|
|
299 | (2) |
|
3 Transfection of D1R and D5R Expression Constructs in HEK293 Cells |
|
|
301 | (2) |
|
4 Radioligand-Binding Assays |
|
|
303 | (2) |
|
|
305 | (8) |
|
6 Results Validating Experimental Approaches |
|
|
313 | (11) |
|
|
324 | (2) |
|
|
326 | (1) |
|
|
327 | (2) |
|
17 Identification of Gain-of-Function Variants of the Human Prolctin Receptor |
|
|
329 | (28) |
|
|
|
|
|
330 | (3) |
|
2 Experimental Procedures |
|
|
333 | (12) |
|
3 Identification of Constitutive Activity: Results and Discussion |
|
|
345 | (8) |
|
|
353 | (1) |
|
|
353 | (1) |
|
|
353 | (4) |
|
18 Investigations of Activated ACVR1/ALK2, a Bone Morphogenetic Protein Type I Receptor, That Causes Fibrodysplasia Ossificans Progressiva |
|
|
357 | (18) |
|
|
|
|
|
|
|
|
|
358 | (1) |
|
|
359 | (3) |
|
|
362 | (4) |
|
|
366 | (3) |
|
|
369 | (2) |
|
|
371 | (1) |
|
|
371 | (4) |
|
19 Identification and Evaluation of Constitutively Active Thyroid Stimulating Hormone Receptor Mutations |
|
|
375 | (22) |
|
|
|
|
|
376 | (6) |
|
2 TSHR Gene Mutational Screening |
|
|
382 | (4) |
|
3 Determination of TSHR Constitutive Activity In Vitro |
|
|
386 | (2) |
|
4 Measurement of TSHR Expression at Cell Surface by Flow Cytometry Analysis |
|
|
388 | (1) |
|
5 TSH-TSHR Binding Assays |
|
|
389 | (2) |
|
6 TSHR Phosphorylation Analysis |
|
|
391 | (1) |
|
|
392 | (1) |
|
|
392 | (5) |
|
20 Assessment of Constitutive Activity of a G Protein-Coupled Receptor, Cpr2, in Cryptococcus neoformans by Heterologous and Homologous Methods |
|
|
397 | (16) |
|
|
|
|
1 Introduction of Receptors and Constitutive Receptors |
|
|
398 | (1) |
|
2 Identification of Cpr2 as a Natural Occuring Constitutively Active Receptor |
|
|
399 | (10) |
|
3 Additional Constitutively Active Receptors Identified in Fungi |
|
|
409 | (1) |
|
|
409 | (1) |
|
|
409 | (4) |
|
21 In Vitro and In Vivo Assessment of Mu Opioid Receptor Constitutive Activity |
|
|
413 | (32) |
|
|
|
|
|
|
|
|
414 | (1) |
|
2 Measuring Opioid Receptor Constitutive Activity in Vitro |
|
|
415 | (10) |
|
3 cAMP Quantification Assay in CHO Cells Expressing Cloned Opioid Receptors |
|
|
425 | (5) |
|
4 In Vivo Assessment of Antagonist Potency in Opioid Naive Subjects |
|
|
430 | (5) |
|
5 In Vivo Assessment of Antagonist Potency to Precipitate Withdrawal |
|
|
435 | (5) |
|
|
440 | (1) |
|
|
441 | (1) |
|
|
441 | (4) |
|
22 Constitutively Active μ-Opioid Receptors |
|
|
445 | (26) |
|
|
|
|
446 | (1) |
|
2 Methods for Measuring Constitutive Activity |
|
|
447 | (18) |
|
|
465 | (1) |
|
|
465 | (1) |
|
|
466 | (5) |
|
23 Protein Kinase CK2 is a Constitutively Active Enzyme that Promotes Cell Survival: Strategies to Identify CK2 Substrates and Manipulate its Activity in Mammalian Cells |
|
|
471 | (24) |
|
|
|
|
|
|
|
|
|
472 | (2) |
|
2 Purification of CK2 for In Vitro Studies |
|
|
474 | (7) |
|
3 Assays for CK2 Activity |
|
|
481 | (4) |
|
4 Modulation of CK2 in Mammalian Cells |
|
|
485 | (6) |
|
|
491 | (1) |
|
|
491 | (1) |
|
|
492 | (3) |
|
24 Assessment of CK2 Constitutive Activity in Cancer Cells |
|
|
495 | |
|
|
|
|
|
|
496 | (3) |
|
2 Assay of CK2 in Crude Biological Samples |
|
|
499 | (5) |
|
3 In-Cell Assay of Endogenous CK2 Activity |
|
|
504 | (2) |
|
4 Identification/Validation of in Vivo CK2 Targets with Specific Inhibitors |
|
|
506 | (5) |
|
|
511 | (1) |
|
|
511 | |